Project Grant HT94252310312
Award Date
9/1/23
Completion Date
8/31/25
Dollars Obligated
$704K
Federal Agency
Defense Health Agency
Federal Grant Program
12.420
Assistance Type
Project Grant
Place of Performance
Potomac, MD 20850, USA
Similar Awards
This federal Project Grant award, valued at $1,103,084.00, was issued by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program. The funding supports the development of a personalized blood-based diagnostic assay for early detection of Amyotrophic Lateral Sclerosis (ALS) at Arizona State University. The university will collaborate with a sub-awardee, Georgetown University, to conduct the research. The project aims to transform healthcare for...
The federal Project Grant award, valued at $962,713.00 and awarded on June 15, 2025 by the Defense Health Agency, supports research to develop robust subtype markers for patient stratification in amyotrophic lateral sclerosis (ALS) under the Military Medical Research and Development (CFDA 12.420) program. The research, conducted by Arizona State University, aims to transform healthcare for military service members and the broader public by advancing disease prevention, diagnosis, treatment,...
This Project Grant award of $2,163,115.00, provided by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420), supports research conducted by Pathmaker Neurosystems Inc. to develop a noninvasive neuromodulation approach to slow the progression of amyotrophic lateral sclerosis (ALS) by suppressing neuronal hyperexcitability. The research, taking place in Boston, MA, aims to explore this innovative therapeutic method over the 2-year performance period...
This federal Project Grant award of $1,072,079.00 from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420) supports research by the Massachusetts Institute of Technology (MIT) to develop diagnostic biomarkers for clinical subtypes of amyotrophic lateral sclerosis (ALS). The research aims to advance the understanding and treatment of ALS, a neurological disorder, with potential benefits for military service members and the broader public....
The Department of the Army Medical Command awarded a $1,210,500 Project Grant under the Military Medical Research and Development (CFDA 12.420) program to Mayo Clinic to conduct research exploring novel biomarkers for amyotrophic lateral sclerosis (ALS). The 3-year grant, titled "Exploring Novel ALS Biomarkers: Multiomics Approach Utilizing Immunoprofiling, Extracellular Vesicle Analysis, and TDP-43 Aggregation Assays," aims to advance the understanding of ALS pathogenesis and identify...
The Department of the Army Medical Command awarded a $1,181,251 Project Grant under the Military Medical Research and Development (CFDA 12.420) program to the University of California, Los Angeles (UCLA) for the project "NEURONAL EXOSOME-BASED BIOMARKERS FOR ALS DIAGNOSIS AND DISEASE PROGRESSION". The grant, with a performance period from April 15, 2025 to April 14, 2028, supports advanced biomedical research focused on transforming healthcare for military service members and the...
This federal Project Grant award of $1,078,882.00 was provided by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program. The grant supports advanced biomedical research focused on developing innovative therapeutic approaches for amyotrophic lateral sclerosis (ALS) by investigating the multimodal therapeutic actions of donor and host neural stem cells. Key research services include consultation on surgical intervention methods for delivering compounds...
This federal Project Grant award, with a funding amount of $2,180,261.00, was provided by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) federal grant program. The award will support a Phase 1C study of Prosetin, a novel, brain-penetrant MAP4K inhibitor, in participants with Amyotrophic Lateral Sclerosis (ALS). The study will be conducted by Projenx Inc., a small disadvantaged business located in New York, NY, and is expected to run from April 1, 2025...
This federal Project Grant award of $1,392,575.00 from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420) supports a project by Sola Biosciences, Inc. to develop a protein folding-based gene therapy targeting TDP-43 for the treatment of amyotrophic lateral sclerosis (ALS). The project aims to transform healthcare for military service members and the public through innovative biomedical research, with a focus on developing medical solutions...
This $680,591 Project Grant awarded by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) will fund a research project at Wayfinder Biosciences Inc. in Seattle, WA. The project aims to develop a novel small molecule screening approach for directly and selectively targeting repeat expansion RNA in C9ORF72 amyotrophic lateral sclerosis (ALS). The award period runs from June 15, 2025 to June 14, 2026 and seeks to advance disease prevention,...